SequelSEC

BIOXYTRAN, INC BIXT

Pharmaceutical Preparations · CIK 0001445815 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
$191.08K
Fiscal year ended 2017-12-31
Operating income
-$310.59K
Fiscal year ended 2017-12-31
Free cash flow
Unavailable
Fiscal year ended 2017-12-31

BIOXYTRAN, INC (BIXT) reported revenue of $191.08K and net income of -$318.39K for the fiscal year ended 2017-12-31. This page shows 4 annual periods of income statement, balance sheet and cash flow figures normalized from BIOXYTRAN, INC’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Pharmaceutical Preparations.

Income

BIOXYTRAN, INC income by fiscal year, in US dollars, normalized from SEC filings.
Metric2017-12-312016-12-312015-12-312014-12-31
Revenue$191.08K$246.50K$255.82K$275.62K
Cost of revenue$103.98K$96.30K$135.68K$165.98K
Gross profit$87.10K$150.19K$120.14K$109.64K
Operating income-$310.59K-$671.28K-$2.09M-$1.28M
Net income-$318.39K-$696.76K-$2.10M-$1.35M
Research & developmentUnavailableUnavailableUnavailableUnavailable
Weighted-average diluted sharesUnavailableUnavailableUnavailableUnavailable
Pretax incomeUnavailable-$696.76K-$2.10M-$1.35M
Income tax expenseUnavailableUnavailableUnavailableUnavailable
Diluted EPSUnavailableUnavailableUnavailableUnavailable
Selling, general & administrative$397.68K$821.47K$2.21M$1.39M
General & administrativeUnavailableUnavailableUnavailableUnavailable
Selling & marketingUnavailableUnavailableUnavailableUnavailable

Balance

BIOXYTRAN, INC balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2017-12-312016-12-312015-12-312014-12-31
Cash & equivalentsUnavailable$11.09K$3.48K$6.17K
Total assets$110$51.67K$55.82K$113.28K
Current assets$110$26.96K$3.48K$6.17K
Total liabilities$1.42K$342.27K$251.04K$334.74K
Current liabilities$1.42K$342.27K$251.04K$334.74K
Total equity incl. NCI-$1.31K-$290.60K-$195.22K-$221.45K
Temporary (mezzanine) equityUnavailableUnavailableUnavailableUnavailable
Inventory$5.26K$6.27KUnavailableUnavailable
Accounts receivable$22.96K$9.60KUnavailableUnavailable
GoodwillUnavailableUnavailableUnavailableUnavailable
Long-term debtUnavailableUnavailableUnavailableUnavailable
Accounts payableUnavailableUnavailableUnavailableUnavailable

Cash flow

BIOXYTRAN, INC cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2017-12-312016-12-312015-12-312014-12-31
Operating cash flow-$18.52K-$42.39K-$2.69K-$16.32K
Capital expendituresUnavailableUnavailableUnavailableUnavailable
Investing cash flowUnavailableUnavailableUnavailableUnavailable
Financing cash flow$22.70K$50.00KUnavailable$1.80K
Net change in cash$4.18K$7.61K-$2.69K-$14.52K
Stock-based compensationUnavailableUnavailableUnavailableUnavailable
Common dividends paidUnavailableUnavailableUnavailableUnavailable
Common share repurchasesUnavailableUnavailableUnavailableUnavailable
Depreciation & amortizationUnavailableUnavailableUnavailableUnavailable

Derived

BIOXYTRAN, INC derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2017-12-312016-12-312015-12-312014-12-31
Free cash flowUnavailableUnavailableUnavailableUnavailable
Gross margin45.6%60.9%47.0%39.8%
Operating margin-162.5%-272.3%-817.9%-464.7%
FCF marginUnavailableUnavailableUnavailableUnavailable
SBC / revenueUnavailableUnavailableUnavailableUnavailable
Current ratio0.08xUnavailable0.01x0.02x
Revenue YoY growth-22.5%-3.6%-7.2%Unavailable
Net margin-166.6%-282.7%-820.9%Unavailable
R&D / revenueUnavailableUnavailableUnavailableUnavailable
CapEx / revenueUnavailableUnavailableUnavailableUnavailable
Long-term debt / equityUnavailableUnavailableUnavailableUnavailable
Effective tax rateUnavailableUnavailableUnavailableUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open BIXT in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-14View SEC filing
10-Q · Filed 2026-05-15View SEC filing
10-K · Filed 2026-04-15View SEC filing
10-Q · Filed 2025-11-14View SEC filing
10-Q · Filed 2025-08-11View SEC filing
10-Q · Filed 2025-05-15View SEC filing

Companies in the same industry

AAGH AARD ABBV ABCL ABEO ABT ABUS ABVC ACAD ACET ACRS ACRV

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.